| Type | Title | Date Released | |
|---|---|---|---|
6-K | Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity | ||
6-K | Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia | ||
6-K | Optimi Health to Present at the ThinkEquity Conference | ||
SCHEDULE 13G/A | YA II PN, Ltd. (Filed by) | ||
6-K | Optimi Health Appoints Melanie Pump to Board of Directors and Announces Management Changes | ||
6-K | Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply | ||
6-K | Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer | ||
6-K | Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for PTSD | ||
6-K | Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder | ||
6-K | Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | ||
424B3 | SHARE RESALE REGISTRATION | Shares: 21,943,260 | ||
6-K | Optimi Health Corp. Establishes US$100 Million Equity Line of Credit with Seven Knots, LLC |